We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Adocia Reports Positive Phase I Clinical Results on HinsBet®, a Fast-Acting Human Insulin
News

Adocia Reports Positive Phase I Clinical Results on HinsBet®, a Fast-Acting Human Insulin

Adocia Reports Positive Phase I Clinical Results on HinsBet®, a Fast-Acting Human Insulin
News

Adocia Reports Positive Phase I Clinical Results on HinsBet®, a Fast-Acting Human Insulin

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Adocia Reports Positive Phase I Clinical Results on HinsBet®, a Fast-Acting Human Insulin"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Adocia, has announced positive results from its phase I clinical study evaluating the safety and clinical utility of HinsBet®, its fast-acting human insulin product for the treatment of diabetes.

The trial compared the product candidate, HinsBet®, to NovoLog® (Novo Nordisk), a fast-acting insulin analog, and Actrapid® (Novo Nordisk), a regular human insulin. It was a double blind study involving 12 healthy volunteers. The pharmacokinetic and pharmacodynamic profiles were obtained using the glucose clamp technique.

On the primary endpoint of safety, HinsBet® showed identical results to the commercial products tested, giving excellent local tolerance and absence of pain at the site of injection.

The onset of action of HinsBet® is as short as NovoLog®’s and shorter than that of Actrapid®. This was demonstrated by insulin profile and glucose infusion rate profile. Moreover, the inter-patient variability on glycemic control with HinsBet® was statistically lower than with NovoLog® or Actrapid®.

HinsBet® is a formulation comprising human insulin and one polymer of the BioChaperone® platform patented by Adocia. Adocia specifically designed this polymer to form a molecular complex with human insulin to accelerate insulin blood penetration.

“We think that we have a unique human insulin formulation which could be a best-in-class insulin product, offering type 1 and 2 diabetics a performance on glycemia control as high as insulin analogs but in a more cost-effective way and with less variability,” said Dr Gérard Soula, Adocia’s President and CEO.

“This fast-acting human insulin fulfills all requirements of FDA and EMA for insulin products and is easily injected with all insulin devices,” said Dr Olivier Soula, Vice President of Adocia and R&D Director. “This is the first completed human study which shows the potential of Adocia’s BioChaperone® as a radically new way of delivering therapeutic proteins.”

Following the results of this phase I trial, Adocia is preparing a phase IIa study on type 1 diabetics to confirm the fast onset of action and the reduction of variability of HinsBet® in comparison to NovoLog®. The company plans to leverage the results of its HinsBet development by partnering with a company involved in the diabetic field.

Advertisement